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The incidence of brain metastases has increased in patients
with NSCLC as a result of better systemic disease control and
advances in imaging modalities. Whole brain radiotherapy
(WBRT) has been the mainstay treatment of multiple
symptomatic brain metastases for years. A number of recent
publications have questioned its place in the absence of a
survival and quality of life benefit and the possible risk for
long-term neurotoxicity. Omission or deferral of WBRT and
strategies consisting of stereotactic radiosurgery or delivery
of systemic therapies alone are being proposed more and
more. However, critical analysis of the literature shows that
WBRT still has relevant indications in well-selected patients.
Within this review, we discuss the place of WBRT in the
modern management of patients with NSCLC.
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Brain metastases (BMs) are frequent in the natural
history of malignant tumors. In patients with NSCLC, BMs
occur in up to 22% of patients at the time of initial diag-
nosis, and BM will develop in approximately 40% of pa-
tients during their disease.1,2 Furthermore, the incidence
and prevalence of BMs are rising given the advances
in imaging methods and improvements in systemic
control. The latter has resulted in a longer survival and,consequently, more time for development of BMs. With
subsequent deleterious effects onmany critical neurologic
functions, BM is an indicator of poor outcome.3 In the past
years, the backbone of focal treatments included surgery
and/or whole brain radiotherapy (WBRT).4,5 Recent trials
have questioned the relevance of WBRT at a time when
radiosurgery or stereotactic radiotherapy (SRS) is being
used with increasing frequency and when newer efficient
therapies such as targeted molecular compounds and im-
munotherapies have become available.6 Longer survival
observed in patients with stage IV NSCLC has also led to
more careful consideration of the risks for development of
debilitating late complications possibly induced by brain
irradiation.7 On the other hand,WBRTmay still have a role
when delivered to appropriate patients.8–10 This narrative
review reappraises the role ofWBRT as a part of the actual
multimodal management of patients with NSCLC.
Arguments for Contemporary WBRT
Indications
Patients Unsuitable for SRS and/or Surgery
According to significant prognostic factors (age,
Karnofsky performance score [KPS], presence ofJournal of Thoracic Oncology Vol. 12 No. 10: 1467-1477
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1468 Loganadane et al Journal of Thoracic Oncology Vol. 12 No. 10extracranial metastases, and number of BMs) included in
the diagnosis-specific graded prognostic assessment
(DS-GPA), and recursive partitioning analysis (RPA) (the
latter including the primary tumor under control but not
the number of BMs), survival in NSCLC ranges from 3 to
14.8 months.3 Prognostic scores have been incorporated
into treatment decisions, and focal interventions should
preferentially be delivered to patients with a good
prognosis. WBRT alone has usually been the preferred
treatment for patients with multiple BMs unsuitable for
SRS and/or neurosurgical treatment. In this population,
“palliative” WBRT was generally thought to improve
quality of life (QoL) (in patients with neurologic symp-
toms) and possibly survival in comparison with best
supportive care.11,12
However, this was not prospectively assessed until
the recently published noninferiority phase 3 QUARTZ
trial (Table 1). In this study, 538 patients with NSCLC
were randomized to dexamethasone and optimal
supportive care with and without WBRT (20 Gy in five
daily fractions). The primary end point was quality-
adjusted life-years (QALYs). Patients were included
when the physician and or the multidisciplinary team
were “uncertain about the potential benefit of WBRT.”
Systemic treatments were allowed, but details were
not reported in the article, suggesting that some
patients had no systemic treatment options. The
conclusion was that WBRT did not improve QALYs
(there were 46.4 QALY days for the group receiving
optimal supportive care plus WBRT versus 41.7 QALY
days for the other group), overall survival (OS) (hazard
ratio [HR] ¼ 1.06, 95% confidence interval [CI]: 0.90–
1.26) or QoL. One limitation of this trial could be that it
included a large proportion of patients with poor
prognosis, explaining the dismal median survival of 9
weeks. More than a third of the included population
had RPA class III and did not benefit from WBRT. The
multivariable analysis indicated that patients younger
than 60 years and with a KPS of 70 or higher, absence
of extracranial metastases, and controlled primary
tumor (i.e., those in RPA class I/good DS-GPA class)
had superior outcomes with WBRT.13 This difference
did not reach statistical significance, except for
younger patients (p ¼ 0.006), but the trial was also not
powered to detect these differences. On the basis of
these data, WBRT remains a valid option for patients
with NSCLC-GPA with a score of at least 1.5 or patients
in RPA class I, which corresponds to a median survival
of 5.5 months.3
Adjuvant WBRT after SRS
SRS (in single or multiple fractions) has become a
common therapeutic modality for patients with a good
prognosis and limited brain tumor volume. Metastases are
October 2017 WBRT in NSCLC: Is There a Role in 2017? 1469usually small (< 3 cm) and well defined. SRS alone
(without WBRT) is feasible as the initial treatment for
patients with five to 10 BMs. In a prospective non-
randomized study, patients with five to 10 BMs did not
seem to fare worse than those with two to four BMs in
terms of OS, intracranial tumor control, neurologic dete-
rioration and death, leukoencephalopathy, or salvage
treatment.17 An ongoing randomized trial comparing
SRS and WBRT for patients with four to 10 BMs
(NCT02353000) will, it is hoped, better define the role of
SRS in this setting. It should additionally be noted that
SRS does not improve survival, except in the subgroup of
patients with a single BM that was also treated with
WBRT. In this 1:1 randomized phase III trial (Radiation
Therapy Oncology Group [RTOG] 9508 [N ¼ 333, 63%
with lung cancer]), WBRT with or without the addition of
SRS was evaluated. The patients with a single BM treated
with WBRT plus SRS had an OS of 6.5 months compared
with 4.9 months for those treated with WBRT only
(p ¼ 0.0393). Moreover, regardless of number of BMs, at
6 months those in the SRS arm had stable or improved
performance status compared with those in the WBRT
arm (43% versus 27% [p ¼ 0.03]).18
Meanwhile, the impact of adjuvant WBRT after SRS in
patients with a limited number of BMs was assessed
through four randomized trials.19–22 The four studies
consistently reported a significantly decreased rate of
brain failure, including intracranial distant and local
failures, with WBRT (Table 2). The conservative strategy
consisting of SRS without WBRT was associated with
high rates of central nervous system (CNS) tumor failures
(50%–76% versus 15%–47% with WBRT). The advan-
tage in brain control provided by adjuvant WBRT, how-
ever, did not translate into an improvement in OS and
demonstrated a detrimental effect on neurocognitive
function (as measured by the Mini–Mental State Exami-
nation score at 12 months; Hopkins Verbal Learning Test
[HVLT]–Revised score at 4 months; Late Effects Normal
Tissue Task Force Subjective, Objective, Management,
Analytic Scales scores, and cognitive test scores, [see
Table 2]). Two trials even suggested a trend toward
inferior survival with the addition of WBRT, including the
recently reported Alliance trial.20,22 In the latter trial, 213
patients with one to three BMs (68% lung primary) were
randomly assigned to SRS plus WBRT or SRS alone. In the
evaluated patients (half of the population), 3 months af-
ter completion of treatment less cognitive deterioration
was found with SRS alone (40 of 63 patients [63.5%])
than with SRS combined with WBRT (44 of 48 patients
[91.7%]) (a difference of –28.2% [p < 0.001]). Intracra-
nial tumor control rates were increased with the addition
of WBRT as compared with SRS alone (85% versus 50%
at 12 months) whereas OS was not (HR ¼ 1.02). On the
basis of these data, the American Society for RadiationOncology expressed reservations regarding the system-
atic use of adjuvant WBRT.23
Several limitations can still be highlighted in the
interpretation of these trials. First, most patients suc-
cumbed from systemic progression or from other causes,
and this may not have been properly detected in survival
analyses. Second, salvage therapies, including WBRT in
12% to 33% of patients undergoing SRS (and/or
repeated SRS and/or the addition of newer more effec-
tive systemic therapies), may have benefitted patients
randomized to SRS. Third, the patients who benefitted
from WBRT seemed to be those with a favorable prog-
nosis. A secondary analysis of the Japanese trial JROSG
99-1 demonstrated a survival benefit for the subgroup of
patients with NSCLC displaying a favorable DS-GPA score
(2.5–4) and treated with SRS and WBRT versus with SRS
alone (16.7 months versus 10.6 months, respectively
[p ¼ 0.04]).24 Furthermore, most trials did include
patients with different primary tumors, and information
regarding driver mutations was not known.
Postoperative Radiation Therapy
Postoperative WBRT has been assessed for patients
with a single resected BM in a randomized trial by
Patchell et al.14 (see Table 1). In that study, 95 patients
(60 cases of lung cancer) were enrolled, with 49 patients
assigned to the WBRT arm and 46 patients to the
observation arm. Postoperative radiation prevented
brain recurrence at the original site (10% versus 46%)
and distant brain recurrence (14% versus 37%; overall
brain recurrence 18% with WBRT versus 70% without
WBRT). Although fewer neurologic-related deaths were
observed with WBRT, there was no difference in OS.
SRS has been largely used as a postoperative radia-
tion modality despite the absence of a high level of evi-
dence. A multi-institutional randomized trial with 194
patients and one to four BMs was recently presented at
the 2016 American Society for Radiation Oncology
meeting. Patients were randomized to SRS (dose not
provided) or WBRT after surgical resection of one lesion.
Most patients (77%) had a single BM, and a lung tumor
was the primary site for more than half of the patients
(n ¼ 114 [59%]). With a median follow up of 15.6
months, there was no survival difference: the median OS
times with SRS or WBRT were 11.5 months and 11.8
months (p ¼ 0.65), respectively. The rate of cognitive
deterioration at 6 months was higher after WBRT
(85.7%) than after SRS (53.8%) (p ¼ 0.0006). WBRT did
provide higher overall intracranial tumor control: the
rates at 6 and 12 months were 90.0% and 78.6% with
WBRT versus 74.0% and 54.7% with SRS (p < 0.0001).
However, QoL was superior in the SRS arm.25 Future
studies should evaluate whether WBRT still has a role in
patients with a high risk for brain relapse, especially
Table 2. Addition of Whole Brain Radiotherapy after Radiosurgery in Phase III Trials
Indicator
Study
Aoyama19 Chang20 Kocher21 Brown22
SRS þ WBRT SRS SRS þ WBRT SRS Surgery þ WBRT
SRS þ
WBRT Surgery SRS SRS þ WBRT SRS
Patients, n (% with NSCLC) 65 (66) 67 (67) 28 (53) 30 (57) 81 (54) 99 (54) 79 (52) 100 (52) 102 (65) 111 (72)
Primary end point OS Neurocognitive
function
Duration functional
independence
Cognitive
deterioration
at 3 mo
Neurocognitive
function assessment
MMSE score
at 12 mo: 28
27 Drop in HVLT-R
total recall
at 4 mo: 52%
24% LENT/SOMA scales Cognitive
deterioration
at 3 mo: 91.7%
63.5%
RPA
1 17% 12% 11% 23% NP NP NP NP NP NP
2 83% 43% 89% 77% NP NP NP NP NP NP
GPA
0-1 NP NP 10% 10.7% NP NP NP NP NP NP
1.5-2 NP NP 63% 67.9% NP NP NP NP NP NP
3 NP NP 17% 17.9% NP NP NP NP NP NP
3-5 NP NP 10% 3.5% NP NP NP NP NP NP
Salvage WBRT 0% 16.4% 0% 33% 3% (surgery or
SRS þ WBRT)
NP NP 33%
(surgery or SRS)
1% 11.7%
Local brain failure 11% 27% 0% 33% 27% 19% 59% 31% 9.9% 27.2%
Intracranial distant failure 42% 64% 27% 55% 23% 33% 42% 48% 7.7% 24.8%
Any brain failure 47% 76% 27% 73% NP NP NP NP 15.4% 49.5%
Neurologic death 22.8% 19.3% risk for neurological
death with SRS þ
WBRT vs. SRS:
HR ¼ 2.1, p ¼ 0.15
28% (surgery or
SRS þ WBRT)
NP NP 44%
(surgery or SRS)
NP NP
OS 7.5 mo 8 mo 5.7 mo 15.2 mo 10.7 mo 10.9 mo 7.4 mo 10.4 mo
SRS, radiosurgery; WBRT, whole brain radiotherapy; OS: overall survival; MMSE, Mini–Mental State Examination; HVLT-R, Hopkins Verbal Learning Test–Revised; LENT, late effects of normal tissue; SOMA, subjective,
objective, management, analytic; RPA, recursive partitioning analysis; NP, not provided; GPA, graded prognostic assessment; HR, hazard ratio.
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October 2017 WBRT in NSCLC: Is There a Role in 2017? 1471those without a competing risk for death from extra-
cranial metastases. In a large single institutional data-
base with 528 patients, trimodality treatment regimen
(surgery plus SRS plus WBRT) was associated with a
higher median survival than surgery plus SRS or SRS
alone and may be considered for patients with a favor-
able prognosis (DS-GPA score >2.5).26 Potential neuro-
cognitive toxicity results in this setting are awaited.
PCI
Another subset of patients with NSCLC who may
benefit from WBRT are those with microscopic BM and a
low extracranial tumor burden. This hypothesis may be
extrapolated from two recent randomized trials investi-
gating prophylactic cranial irradiation (PCI) in locally
advanced patients with NSCLC who had virtually no
remaining systemic disease (see Table 1). Both trials
reported a reduction in BM occurrence after PCI, but
without effect on survival outcomes. RTOG 0214 closed
early because of slow accrual (356 enrolled patients of
1058 initially planned).15 Patients with stage III NSCLC
without progression after locoregional thoracic treat-
ment (surgery and/or radiation therapy with or without
chemotherapy) were randomly assigned to PCI or
observation. Of note, follow-up included systematic brain
imaging (at 6, 12, 24, 36, and 48 months and then yearly)
after treatment, and this is not current practice in most
centers.27 At 1 year, PCI decreased the rate of BM (7.7%
with PCI versus 18% with observation [p ¼ 0.004])
without a survival benefit. Neurocognitive function and
QoL results were subsequently reported. Patients who
underwent PCI had no Mini–Mental State Examination
score or QoL deterioration, although a decline in mem-
ory (according to the HVLT) was observed at 1 year.28
Long-term results of this trial are awaited. The second
trial compared PCI with observation in patients with
resected stage IIIA-N2 NSCLC after adjuvant chemo-
therapy.16 The actuarial 5-year BM rate was 20.3% with
PCI versus 49.9% in the other group (HR ¼ 0.28,
p < 0.001). The PCI group had significantly longer
disease-free survival (the primary end point): 28.5
months versus 21.5 months (HR ¼ 0.6, p ¼ 0.037). OS
was not significantly improved in the PCI arm (31.2
months versus 27.4 months [p ¼ 0.31]). However, the
trial was terminated early after inclusion of 156 patients
(of 254 initially planned), and no firm conclusion can be
drawn given the lack of power. A subsequent trial
(NVALT-11/DLCRG-02) assessing PCI in NSCLC was
presented at the American Society of Clinical Oncology
annual meeting this year. The primary objective was to
determine whether PCI decreases the proportion of
patients in whom symptomatic BMs develop at 24
months. Initially, 300 patients had to be randomized to
detect a 17% decrease in the PCI arm with a 90% power.Because of slow accrual, 175 patients were randomized
and it was decided to stop accrual. With a median follow-
up of 48.5 months, the proportion of patients with
symptomatic BM (the primary end point) was 4.6% in
the PCI arm and 28.4% in the control arm (p < 0.00001).
Median OS was 24.2 months in the PCI arm versus 21.9
months in the control arm (p ¼ 0.52).29
Comparison with the SCLC model is interesting
because it may help us understand some issues related to
WBRT in NSCLC. PCI in SCLC was the only brain radio-
therapy method leading to improvement in survival.30,31
One should be aware that use of PCI in SCLC was
controversial until the publication of the meta-analysis
based on individual data, which included 987 patients
with a complete response after chemotherapy.30 In fact,
most randomized trials demonstrated only a reduction in
the rate of incidence of BM.7 The European Organization
for Research and Treatment of Cancer trial was the sole
trial to report a benefit in OS for extensive-stage disease
in response to induction therapy.31 Interestingly, oppo-
nents of PCI at that time argued about the absence
of survival benefit and long-term sequelae. PCI is now
a standard in patients with SCLC with good response
to frontline treatment in spite of prospective data
mentioning increased adverse effects. In the randomized
trial PCI 99-01 comparing the PCI dose of 25 or 36 Gy in
720 patients with limited SCLC, mild but significant de-
teriorations of communication deficit, fatigue, intellectual
deficit, and memory loss were detected across time.32 The
QoL analysis of the European Organization for Research
and Treatment of Cancer trial also reported a negative
impact of PCI at 6 weeks.33 It should be acknowledged
that the risk for development of BM in patients with SCLC
is probably higher than that for patients with NSCLC. PCI
may thus be especially useful in patients with NSCLC with
a theoretically higher BM risk (e.g., young, female,
adenocarcinoma, and high–N status patients).Combination of WBRT with Systemic
Treatments
Patients with Targetable Driver Mutations
Over the past decade, major advances have been made
in the understanding of NSCLC molecular biology. EGFR
mutations and ALK receptor tyrosine kinase gene (ALK)
translocation represent tumor driver mutations that
dramatically predict response to specific tyrosine kinase
inhibitors (TKIs) in patients with stage IV adenocarci-
nomas. Those patients consequently have a natural his-
tory and a prognosis that differ completely from those of
patients with wild-type tumors.34 An update of the GPA
score (GPA for Lung Cancer Using Molecular Markers)
integrating molecular markers EGFR and ALK was
recently proposed.35 Data from 2186 patients (time
1472 Loganadane et al Journal of Thoracic Oncology Vol. 12 No. 10period 2006–2014) with NSCLC and newly diagnosed BM
(1521 adenocarcinomas and 665 nonadenocarcinomas)
was analyzed. Significant prognostic factors included the
original four factors plus EGFR and ALK alterations in
patients with adenocarcinoma. The median OS was 12
months, but patients with NSCLC-adenocarcinoma with a
Lung-molGPA score of 3.5 to 4.0 had an OS of nearly 4
years. Therefore, future studies should be designed taking
these new clinically relevant parameters into account.
Although EGFR/ALK mutations/translocations in pa-
tients with NSCLC are associated with improved
outcome when those patients are treated with TKI, there
is debate as to whether BMs are prone to develop in
them versus in patients with wild-type tumors. A
retrospective Chinese study on 1063 patients with
NSCLC suggested that those harboring mutations
involving EGFR exon 19 (deletion) but not exon 21 were
at higher risk for BM than those with wild-type tumors.36
Eichler et al. demonstrated that patients bearing EGFR
mutations were more likely to have multiple BMs, but
there was no difference in the rate of leptomeningeal
metastases.37 Similarly, a study on ALK-translocated
tumors before the era of anti-ALK TKI showed an
increased rate of intracranial failure.38 Other teams
conversely found no difference or a decrease in BM
occurrence between wild-type and EGFR/ALK NSCLC at
baseline evaluation.39,40 In any case, patients with a
driver mutation and long-term survival are especially
prone to development of BM, as in patients with a
survival beyond 5 years, the percentage of patients with
BM increases to 52.9%.41
First-generation TKIs targeting the EGFR and ALK
pathways (erlotinib, gefinitib, and crizotinib) demon-
strated a major response rate and progression-free
survival benefit compared with conventional chemo-
therapy.42–44 Encouraging results were also reported in
the CNS with these targeted therapies. However, strate-
gies based exclusively on TKIs without local therapy
have led to inferior intracranial control (11%–26%
versus 50%–77% for patients with NSCLC receiving
chemotherapy).45 The high rate of intracranial failure is
attributable to both poor intracranial penetration of
especially first-generation TKIs and the emergence of
intrinsic tumor resistance mechanisms.46 Moreover,
mutations in the metastatic site may differ from those in
the primary tumor in up to 33% of cases.47 Furthermore,
a multi-institutional retrospective study demonstrated
that the use of upfront EGFR TKI therapy and deferral of
radiation therapy (SRS or WBRT) was associated with
inferior survival.48 Likewise, a retrospective analysis
from randomized trials in patients with BM and
ALK rearrangement who were receiving crizotinib
highlighted an increased median intracranial time to
progression (TTP) for locally pretreated (with brainradiotherapy) patients (13.2 versus 7 months, respec-
tively). Intracranial median TTP was 7 months and sys-
temic TTP was 12.5 months in patients who did not
receive brain-specific treatment. This underscores that
brain is a main primary site of relapse in nonirradiated
patients treated with a TKI with poor blood-brain barrier
penetration.49 However, an impressive median survival
of 49.5 months was seen in 90 patients with NSCLC
treated with both radiation (WBRT or SRS) and crizoti-
nib.50 It should be highlighted that 41 patients also
received a second-generation ALK inhibitor and this may
have accounted for the observed increased outcomes.
Second- and third-generation ALK inhibitors (cer-
itinib, alectinib, brigatinib, and lorlatinib) demonstrated
a more favorable pharmacokinetic profile with greater
CNS penetration.46,51,52 Prospective research concerning
the CNS activity of second- and newer-generation TKIs is
ongoing. Possibly, these newer TKIs can change the need
for local treatments. Striking results were reported with
alectinib (a second-generation ALK inhibitor) at the
2017 American Society of Clinical Oncology meeting. In a
phase III, open label, randomized trial comparing alec-
tinib with crizotinib, the time to CNS progression was
significantly longer with alectinib in the intention-to-
treat population (cause-specific HR ¼ 0.16, p < 0.001);
18 patients in the alectinib group (12%) had an event of
CNS progression, as compared with 68 patients in the
crizotinib group (45%). The cumulative incidence rate of
CNS progression was consistently lower with alectinib
than with crizotinib, and the 12-month cumulative inci-
dence rate of CNS progression was 9.4% versus 41.4%.
The median duration of intracranial response was 17.3
months (95% CI: 14.8–not estimable) and 5.5 months
(95% CI: 2.1–17.3), respectively. Among patients with
measurable or nonmeasurable CNS lesions at baseline,
a CNS response occurred in 38 of 64 patients in the
alectinib group (59%) and in 15 of 58 patients in the
crizotinib group (26%); 29 patients in the alectinib
group (45%) had a complete CNS response, as compared
with five patients in the crizotinib group (9%). There-
fore, it appears reasonable to delay the WBRT for brain
metastatic ALK-translocated tumors in first-line treated
with alectinib. It then seems reasonable to postpone
WBRT in patients with NSCLC with targetable driver
mutations. Whether the association of WBRT and spe-
cific TKIs (both in patients with EGFR-mutated NSCLC
and in patients with ALK-rearranged NSCLC) could be
synergistic is additionally evaluated in clinical trials (e.g.,
NCT01518621 or NCT02714010).
Patients without Targetable Driver Mutation
It is generally admitted that systemic treatments
should be initiated in nonsymptomatic patients with
multiple BMs; as with first-line chemotherapy, the
October 2017 WBRT in NSCLC: Is There a Role in 2017? 1473intracranial response rate is similar or only slightly
lower than the extracranial response rate, resulting in
deferral or omission of WBRT.10 To improve outcomes,
several chemotherapeutic regimens have been tested
concurrently with WBRT in patients with NSCLC, but
with disappointing results.53–55 The role of temozolo-
mide associated with WBRT in NSCLC is controversial.
Although some studies have reported good response
rates and limited toxicity,56,57 others (including the
prematurely stopped RTOG 0302 phase III trial) have
demonstrated deleterious effects.58,59
In the context of the growing place of immune
checkpoint blockers targeting the programmed cell
death 1 axis in NSCLC,60,61 preliminary data are
becoming available for patients with BM. Pem-
brolizumab showed intracranial activity in six of 18
patients with NSCLC (33%) enrolled in a phase II trial.62
Nivolumab, however, led to discontinuation of treatment
on account of exacerbation of neurologic symptoms in
seven of 12 patients with CNS metastasis who dis-
continued it [58%].63 This could correspond to pseudo-
progressive or hyperprogressive disease described in
patients treated with anti–programmed cell death 1/
programmed death ligand 1.64,65 Whether WBRT mayFigure 1. Possible spectrum of indications for whole brain rad
tases (BMs). CTL, cytotoxic T lymphocyte; PD-1, programmed c
prophylactic cranial irradiation; EGF, epidermal growth facto
inhibitor; SRS, stereotactic radiosurgery.potentially limit this rare CNS effect or potentiate the
efficacy of immunotherapy should be further evaluated
in carefully selected patients.66,67
Prospects
Future Selection of Patients in Clinical Trials
All four randomized trials testing the role of adjuvant
WBRT enrolled patients with several primary tumors.
Although more and more studies for systemic therapies
are based on specific biomarkers, most SRS and WBRT
trials included a large variety of tumors that have nothing
in common apart from the presence of BM. However, it
should be emphasized that NSCLC represented most cases
in almost all the trials of cranial irradiation. Even within
the same histologic subtype, management is now driven
by genetic profile. Selection of patients for adjuvant
WBRT is a critical issue because the patients who would
benefit are those with initially good neurocognitive
function, young age, KPS of 70 or higher, low extracranial
tumor burden, high DS-GPA or RPA score, or presence of
EGFR/ALK alteration (Lung-molGPA).35 The latter should
also be discussed in light of newer-generation TKIs.
Conversely, in patients with deteriorated baseline neu-
rocognitive function, advanced age, poor KPS, high tumoriotherapy in patients with NSCLC with multiple brain metas-
ell death protein 1; PD-L1, programmed death ligand 1; PCI,
r; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase
1474 Loganadane et al Journal of Thoracic Oncology Vol. 12 No. 10burden, and poor DS-GPA/RPA score, WBRT will not add
any survival or QoL benefit and may even possibly hasten
the death of frail individuals.Expectations in Neuroprotective Strategies
The decreased neurocognitive function after brain
irradiation may potentially link to damage of neural
stems cells in the subventricular zone and hippocam-
pus. Sparing hippocampi during WBRT by using
intensity-modulated radiation therapy could theoreti-
cally reduce the neurocognitive impairment. This was
first tested in the single-arm phase II trial RTOG 0933
(56 of 100 patients enrolled had lung cancer). This trial
showed a mean relative decline of 7% in HVLT-revised
delayed recall at 4 months, which represents a signifi-
cant improvement as compared with the 30% decline of
the historical control.68 Two phase III trials
(NCT02341170 and NCT02448992) are specifically
assessing hippocampus-sparing PCI in locally advanced
NSCLC.
Another strategy relies on the use of neuroprotective
agents; it was tested in two randomized trials. The RTOG
0614 assessed memantine, an oral N-methyl-D-aspartate
receptor antagonist, in patients with BM who were
receiving WBRT. Patients were randomized to receive
either placebo or memantine within 3 days of initiation
of radiotherapy for 24 weeks. From 508 eligible patients
(70% with lung cancer), only 149 were analyzable for
the delayed recall at 24 weeks, which was the primary
end point. There were fewer declines in delayed recall in
the memantine arm at 24 weeks, but the difference was
not statistically significant (p ¼ 0.06). However, the
memantine arm had a significantly longer time to
cognitive decline and superior results regarding execu-
tive function at 8 and 16 weeks and processing speed.69
The second trial enrolled a total of 198 adult patients
with brain tumors who had survived for at least 6
months after partial or WBRT; they were randomly
assigned to receive donepezil, a cholinesterase indicated
in Alzheimer disease, or placebo. A cognitive composite
score assessing memory, attention, language, visuomo-
tor, verbal fluency, and executive functions was defined
as the primary end point. After 24 weeks of treatment,
the composite scores did not differ significantly between
groups, but it resulted in modest improvements in
several cognitive functions, especially among patients
with greater pretreatment impairments.70
Conclusion
The indications for WBRT have decreased, whereas
the indications for SRS have increased. WBRT still has a
role to play in BM management of selected patients with
multiple BMs (Fig. 1). To our viewpoint, and inaccordance with European Society for Medical Oncology
guidelines,10 we discuss WBRT in symptomatic patients
with NSCLC with multiple BMs (large BMs >3 cm and
progressive small metastases with total BM volume >20
cm3) and adequate DS-GPA (>1.5)/RPA (class I or II)
scores. In patients without actionable oncogenic driver
mutations, the main indications include neurologic
symptoms and brain progression after/during front-line
systemic chemotherapy. Adjuvant WBRT has become
exceptional, as our preferred option is adjuvant SRS
(residual tumor and larger size). CNS penetration of
immune checkpoint blockers is currently a topic of
intense search, and no firm suggestion can be made as
yet. WBRT, as well as brain SRS, is postponed in patients
with targetable driver mutation, but these patients
should be closely monitored (brain magnetic resonance
imaging every 2–3 months).71 The role of WBRT will
probably continue to evolve in the coming years. This
will depend on the ability of newer systemic treatments
to cross, alone or in combination, the blood-brain bar-
rier. Optimization of WBRT with pharmacological and
technical innovations to selectively spare organs
involved in the memory process may also decrease the
potential toxicity of WBRT.72References
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